Breaking News

CMC Biologics, Zymeworks Enter Master Services Agreement

September 3, 2014

CMC to provide development, clinical manufacture of antibody candidate

CMC Biologics, Inc. and Zymeworks Inc. have entered into a Master Services Agreement for the process development, formulation development, and cGMP clinical manufacture of a recombinant human IgG1 bi-specific (heterodimeric) antibody.
 
"Being selected by Zymeworks, who are known for developing best-in-class and highly effective protein therapeutics, is a natural fit for us and validates our technical excellence and partnering philosophy," said Gustavo Mahler, Ph.D., global chief operations officer of CMC Biologics. "Through this agreement, Zymeworks and CMC Biologics will work together to advance the next frontier of bi-specific antibody development platforms and bring novel therapies to patients in need."
 
"As we advance our lead Azymetric oncology program and first therapeutic built on our proprietary ZymeCAD platform, choosing a contract partner with a track record of success in development and manufacturing is critical," said Ali Tehrani, Ph.D., president and chief executive officer of Zymeworks.  "Our collaboration with CMC Biologics helps position us to move our oncology program into clinical trials for the treatment of breast cancer and other solid tumors, as well as subsequent therapeutic candidates targeted towards hematological cancers such as leukemia and lymphoma."
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research